Shots:

• The FDA’s BT & EMA’s PRIME designation is based on P-IIb trial results assessing MEDI8897 in patients with LTRI caused by respiratory syncytial virus (RSV) in premature infants @150 days
• The P-IIb study resulted in meeting its 1EPs with reduction in the incidence of medically-attended LRTI
• MEDI8897 is an extended half-life RSV F mAb- used for prevention of LRTI administered as a single dose within 5months and has received FDA’s FT designation in Mar-2015. In Mar- 2017 AstraZeneca and Sanofi Pasteur collaborated to jointly commercialize MEDI8897

   Ref: AstraZeneca | Image: AstraZeneca